Back to Search
Start Over
The potential for Lactoferrin to reduce SARS-CoV-2 induced cytokine storm.
- Source :
-
International immunopharmacology [Int Immunopharmacol] 2021 Jun; Vol. 95, pp. 107571. Date of Electronic Publication: 2021 Mar 12. - Publication Year :
- 2021
-
Abstract
- The COVID-19 pandemic is a serious global health threat caused by severe acute respiratory syndrome of coronavirus 2 (SARS-CoV-2). Symptoms of COVID-19 are highly variable with common hyperactivity of immune responses known as a "cytokine storm". In fact, this massive release of inflammatory cytokines into in the pulmonary alveolar structure is a main cause of mortality during COVID-19 infection. Current management of COVID-19 is supportive and there is no common clinical protocol applied to suppress this pathological state. Lactoferrin (LF), an iron binding protein, is a first line defense protein that is present in neutrophils and excretory fluids of all mammals, and is well recognized for its role in maturation and regulation of immune system function. Also, due to its ability to sequester free iron, LF is known to protect against insult-induced oxidative stress and subsequent "cytokine storm" that results in dramatic necrosis within the affected tissue. Review of the literature strongly suggests utility of LF to silence the "cytokine storm", giving credence to both prophylactic and therapeutic approaches towards combating COVID-19 infection.<br /> (Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.)
- Subjects :
- Animals
COVID-19 complications
Cytokine Release Syndrome etiology
Cytokine Release Syndrome immunology
Cytokines metabolism
Gastrointestinal Microbiome immunology
Humans
Lung immunology
Lung pathology
Respiratory Distress Syndrome immunology
Respiratory Distress Syndrome therapy
COVID-19 therapy
Cytokine Release Syndrome therapy
Lactoferrin immunology
Lactoferrin therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1878-1705
- Volume :
- 95
- Database :
- MEDLINE
- Journal :
- International immunopharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 33765614
- Full Text :
- https://doi.org/10.1016/j.intimp.2021.107571